Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia

Neuropsychopharmacology

Volumn 23, Issue 2, 2000, Pages 170-177

  Hori, Hiroko ^a   Ohmori, Osamu ^a   Shinkai, Takahiro ^a   Kojima, Hideki ^a   Okano, Chie ^a   Suzuki, Takashi ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Association study; Polymorphism; Schizophrenia; Superoxide dismutase; Tardive dyskinesia

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGE DISTRIBUTION; ALLELES; CASE-CONTROL STUDIES; COMORBIDITY; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SUPEROXIDE DISMUTASE;

EID: 0034096258     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00156-6     Document Type: Article

References (36)

1. Adler L.A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., Angrist B. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 150:1993;1405-1407.
2. Armstrong M., Daly A.K., Blennerhassett R., Ferrier N., Idle J.R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry. 170:1997;23-26.
3. Borgstahl G.E., Parge H.E., Hickey M.J., Johnson M.J., Boissinot M., Hallewell R.A., Lepock J.R., Cabelli D.E., Tainer J.A. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. Biochemistry. 35:1996;4287-4297.
4. Casey D.E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res. 4:1991;109-120.
5. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., Wyatt R.J. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 149:1992;773-777.
6. Esteban J., Rosen D.R., Bowling A.C., Sapp P., MuKenna-Yasek D., O'Regan J.P., Beal M.F., Horvitz H.R., Brown R.H. Jr. Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis. Human Mol Genet. 3:1994;997-998.
7. Grasbon-Frodl E.M., Kösel S., Riess O., Müller U., Mehraein P., Graeber M.B. Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem Biophys Res Commun. 255:1999;749-752.
8. 0 state) restores growth of a manganese-superoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. Evidence for electron transport as a major source of superoxide generation in vivo. J Biol Chem. 268:1993;26699-26703.
9. Gutteridge J.M. Iron and oxygen radicals in brain. Ann Neurol. 32(Suppl):1992;S16-S21.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 534-537. 1976;US Department of Health, Education and Welfare, Washington, DC.
11. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry. 30:1991;795-805.
12. Jeste D.V., Kelsoe J.R. Schizophrenia, tardive dyskinesia, and D3 receptor gene variant. A new twist on dyskinesias? Mol Psychiatry. 2:1997;86-88.
13. Kane J.M., Smith J.M. Tardive dyskinesia. Arch Gen Psychiatry. 39:1982;473-481.
14. Latimer P.R. Tardive dyskinesia. A review Can J Psychiatry. 40(Suppl 2):1995;S49-S54.
15. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry. 28:1990;535-539.
16. Lohr J.B., Caligiuri M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 57:1996;167-173.
17. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr Res. 15:1995;66.
18. Malhotra A.K., Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry. 45:1999;544-550.
19. Matsumoto T., Uchimura H., Hirano M., Kim J.S., Yokoo H., Shimomura M., Nakahara T., Inoue K., Oomagari K. Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain. Eur J Pharmacol. 89:1983;27-33.
20. Miller C.H., Simioni I., Oberbauer H., Schwitzer J., Barnas C., Kulhanek F., Boissel K.E., Meise U., Hinterhuber H., Fleischhacker W.W. Tardive dyskinesia prevalence rates during a ten-year follow-up. J Nerv Ment Dis. 183:1995;404-407.
21. Mukherjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res. 19:1996;19-26.
22. th World Congress on Psychiatric Genetics, Bonn, Germany. Am J Med Genet. 81:1998;527.
23. Ohmori O., Suzuki T., Kojima H., Shinkai T., Terao T., Mita T., Abe K. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res. 32:1998;107-113.
24. Pall H.S., Williams A.C., Blake D.R., Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet. ii:1987;596-599.
25. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry. 30:1991;409-412.
26. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 39:1982;486-487.
27. Schwarts P.J., Reaume A., Scott R., Coyle J.T. Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Res. 789:1998;32-39.
28. Segman R., Neeman T., Heresco-Levy U., Finkel B., Karagichev L., Schlafman M., Dorevitch A., Yakir A., Lerner A., Shelevoy A., Lerer B. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 4:1999;247-253.
29. Sham P.C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 59:1995;97-105.
30. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawara-Hattori Y., Shimizu Y., Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophys Res Commun. 226:1996;561-565.
31. Shimoda-Matsubayashi S., Hattori Y., Matsumine H., Shinohara A., Yoritaka A., Mori H., Kondo T., Chiba M., Mizuno Y. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology. 49:1997;1257-1262.
32. Steen V.M., Løvlie R., MacEwan T., McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 2:1997;139-145.
33. Sweet R.A., Mulsant B.H., Gupta B., Rifai A.H., Pasternak R.E., McEachran A., Zubenko G.S. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry. 52:1995;478-486.
34. Toru M. Seishinbunretsubyo no yakuri (Pharmacology in schizophrenia). 1983;Chu-gai Igakusha Co, Tokyo, Japan.
35. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 155:1998;1207-1213.
36. Yamada K., Kanba S., Anamizu S., Onishi I., Ashikari G., Yagi G., Asai M. Low superoxide dismutase activity in schizophrenia patients with tardive dyskinesia. Psychol Med. 27:1997;1223-1225.